Related Experiment Video
Updated: May 21, 2025
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
Published on: September 3, 2013
Novel Application of Lutetium-177-Prostate Specific Membrane Antigen (LuPSMA) Radioligand Therapy for Metastatic
Rhiannon S McBean1, Annaleis M Tatkovic1, Sepinoud Firouzmand1
1I-MED Radiology Network, Brisbane, Queensland, Australia.
Abstract:
Intracranial synovial sarcoma is exceedingly rare, with only 24 cases reported in the literature. Given prostate specific membrane antigen (PSMA) expression is found in the neovascular endothelium of solid tumours, including sarcomas, Lutetium-177-PSMA (LuPSMA) presents a potential therapeutic option. The case presented here describes the first application of LuPSMA in a patient with synovial sarcoma. Our patient, a 27-year-old female underwent seven LuPSMA treatment cycles over the last 8 months of her life. Disease stability and prolongation in time to progression was observed across the treatment course with subjective tumour regression also seen after two cycles. Overall, our initial experience with this novel approach demonstrates proof-of-principle of LuPSMA treatment beyond prostate cancer, for patients with other PSMA-expressing cancer diseases.
More Related Videos
09:49A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods
Published on: April 24, 2020
09:5718F-Labeling of Radiotracers Functionalized with a Silicon Fluoride Acceptor SiFA for Positron Emission Tomography
Published on: January 11, 2020